AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11098560 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 0
Study 11098560 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic agents
Number of subjects: 0
Study 9328156 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (300 mg/day i.v. for 5 days followed by 1.6 g/day orally for 12 months)
Number of subjects: 57
Study 9328156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 8104200 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (mean dose, 120 mg/day) combined with fluphenazine (mean dose, 28 mg/day)
Number of subjects: 6
Study 8104200 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine alone
Number of subjects: 6
Study 8104200 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan
Number of subjects: 6
Study 4042078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl loflazepate 2 mg
Number of subjects: 0
Study 4042078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl loflazepate 4 mg
Number of subjects: 0
Study 4042078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl loflazepate 6 mg
Number of subjects: 0
Study 4042078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl loflazepate 8 mg
Number of subjects: 0
Study 4042078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28984097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative epidural infusion started preoperatively and maintained throughout
Number of subjects: 40
Study 28984097 — intervention group
Group type: COMPARATOR
Intervention: Postoperative initiation of epidural infusion after neurological examination
Number of subjects: 40
Study 27655371 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal electromyographic (EMG) biofeedback associated with prophylactic pharmacological therapy
Number of subjects: 27
Study 27655371 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment alone (Control Group)
Number of subjects: 27
Study 23851514 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 160
Study 21527896 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention (phase I) followed by maintenance interventions (phase II) for 30 months
Number of subjects: 1032
Study 21527896 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I weight loss
Number of subjects: 1032
Study 21527896 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern at entry, improvement in dietary pattern
Number of subjects: 1032
Study 21527896 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain during phase II
Number of subjects: 1032
Study 20601737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion at a dosage of 0.3 g/kg
Number of subjects: 12
Study 20601737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20084795 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed beam of 6‐Mev electrons (10Gy) and opposed tangential fields using 6 Mev‐photons (36 Gy) followed by 6‐Mev electrons boost to the scar of mastectomy for 4 Gy/2 fractions
Number of subjects: 22
Study 20084795 — intervention group
Group type: COMPARATOR
Intervention: Non-iscocentric technique
Number of subjects: 22
Study 20084795 — intervention group
Group type: COMPARATOR
Intervention: Isocentric technique
Number of subjects: 22
Study 20084795 — intervention group
Group type: COMPARATOR
Intervention: Both treatment arms
Number of subjects: 22
Study 15647411 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg oral suspension
Number of subjects: 24
Study 15647411 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg oral suspension (hemodialysis-dependent subjects)
Number of subjects: 24
Study 14512128 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (BANS) - 64-microg total dose (one 32-microg spray per nostril)
Number of subjects: 371
Study 14512128 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (BANS)
Number of subjects: 371
Study 14512128 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate nasal spray (FPNS) - 200-microg total dose (two 50-microg sprays per nostril in study 1) and 100-microg total dose (one 50-microg spray per nostril in study 2)
Number of subjects: 371
Study 10580711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high-frequency electromagnetic field (EMF) exposure (900 MHz; maximum specific absorption rate 1 W/kg) during night-time sleep
Number of subjects: 0
Study 10580711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high-frequency electromagnetic field (EMF) exposure
Number of subjects: 0
Study 10580711 — intervention group
Group type: COMPARATOR
Intervention: Control night with sham exposure
Number of subjects: 0
Study 8759957 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory sample discrimination task with tonal sequences
Number of subjects: 0
Study 8759957 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sequence length
Number of subjects: 0
Study 8759957 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased component duration
Number of subjects: 0
Study 8759957 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced overlap in distributions
Number of subjects: 0
Study 1895262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (initial daily dose 5 mg/kg)
Number of subjects: 92
Study 1895262 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (initial daily dose 250 mg)
Number of subjects: 92
Study 6822085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional assessment and support in ICU patients
Number of subjects: 84
Study 6822085 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 84
Study 31729326 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate blood transfusion (higher volume: 30 mL/kg whole blood / 15 mL/kg packed cells; lower volume: 20 mL/kg whole blood / 10 mL/kg packed cells)
Number of subjects: 0
Study 31729326 — intervention group
Group type: COMPARATOR
Intervention: Immediate blood transfusion (20 mL/kg whole blood equivalent)
Number of subjects: 0
Study 28323798 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 80% (Supplemental perioperative oxygen therapy)
Number of subjects: 0
Study 28323798 — intervention group
Group type: COMPARATOR
Intervention: FiO2 30% (Control group)
Number of subjects: 0
Study 26515269 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin (0.5 mg/kg)
Number of subjects: 92
Study 26515269 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 92
Study 24486687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.2% Glyceryl Trinitrate and 2% lignocaine ointment (Group A)
Number of subjects: 192
Study 24486687 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine ointment (Group B)
Number of subjects: 192
Study 24486687 — intervention group
Group type: COMPARATOR
Intervention: 0.2% Glyceryl Trinitrate ointment (Group C)
Number of subjects: 192
Study 21769664 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 7868
Study 21769664 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident clinical fractures
Number of subjects: 7868
Study 21769664 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident clinical vertebral fractures
Number of subjects: 7868
Study 21769664 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment <3 months post fracture
Number of subjects: 7868
Study 19393880 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric IOL group
Number of subjects: 3
Study 19393880 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical IOL group
Number of subjects: 3
Study 19393880 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 17244902 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric loading
Number of subjects: 75
Study 17244902 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive low-energy shock-wave therapy (SWT)
Number of subjects: 75
Study 17244902 — intervention group
Group type: COMPARATOR
Intervention: Wait and see
Number of subjects: 75
Study 15978302 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 250/50 microg BID (FSC)
Number of subjects: 361
Study 15978302 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium/albuterol 36/206 microg QID (IB/ALB)
Number of subjects: 361
Study 12785670 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy conservation course
Number of subjects: 37
Study 12785670 — intervention group
Group type: COMPARATOR
Intervention: Control period of traditional treatment
Number of subjects: 37
Study 10234599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 1000 mg q8h with zalcitabine 0.75 mg q8h
Number of subjects: 0
Study 10234599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 1000 mg q8h with stavudine 40 mg q12h
Number of subjects: 0
Study 10234599 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir 1000 mg q8h alone
Number of subjects: 0
Study 8598547 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg vitamin A (retinyl palmitate)
Number of subjects: 165
Study 8598547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 8598547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplemented infants with normal RDR
Number of subjects: 165
Study 8598547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplemented infants with abnormal RDR
Number of subjects: 165
Study 8598547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplemented infants
Number of subjects: 165
Study 1959720 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol, 0.2 mg 4 times daily for 7 days
Number of subjects: 80
Study 1959720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7034771 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral iridectomy with thermal sclerostomy
Number of subjects: 15
Study 7034771 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 15
Study 7034771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 31801245 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 111
Study 31801245 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 111
Study 31801245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus GnRHa
Number of subjects: 111
Study 28544279 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief scripted education and advice on percentage probability of falling in the next 6 months; intervention group size: 63 patients.
Number of subjects: 412
Study 28544279 — intervention group
Group type: COMPARATOR
Intervention: Control group; size: 67 patients.
Number of subjects: 412
Study 28544279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (brief education).
Number of subjects: 412
Study 28544279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (brief education) for patients presenting with a fall.
Number of subjects: 412
Study 28544279 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 412
Study 25010996 — intervention group
Group type: EXPERIMENTAL
Intervention: barefoot
Number of subjects: 35
Study 25010996 — intervention group
Group type: COMPARATOR
Intervention: uncushioned minimalist shoes
Number of subjects: 35
Study 25010996 — intervention group
Group type: COMPARATOR
Intervention: cushioned ultraflexible shoes
Number of subjects: 35
Study 25010996 — intervention group
Group type: COMPARATOR
Intervention: standard running shoes
Number of subjects: 35
Study 23375357 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (VIB)
Number of subjects: 57
Study 23375357 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical balance training (BAL)
Number of subjects: 57
Study 21911534 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 115
Study 21911534 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 115
Study 21911534 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in alignment
Number of subjects: 115
Study 19281636 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 40 mg/kg praziquantel with 2 weeks interval
Number of subjects: 0
Study 19281636 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 40 mg/kg praziquantel
Number of subjects: 0
Study 16718542 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families Program (SAAF)
Number of subjects: 172
Study 16718542 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 172
Study 12761264 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 62
Study 12761264 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PTA)
Number of subjects: 62
Study 10636605 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocially enhanced treatment program (PET)
Number of subjects: 84
Study 10636605 — intervention group
Group type: COMPARATOR
Intervention: Case management-oriented outpatient treatment program (CM)
Number of subjects: 84
Study 9077497 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) detection in brain tissue using double-label immunohistochemistry technique
Number of subjects: 6
Study 9077497 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 association with astrocytes
Number of subjects: 6
Study 9077497 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of IL-6 and HLA-DR expression
Number of subjects: 6
Study 9077497 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of IL-6 in inflammatory demyelinating disorders
Number of subjects: 6
Study 8417772 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence during dental treatment
Number of subjects: 32
Study 8417772 — intervention group
Group type: COMPARATOR
Intervention: Parental absence during dental treatment
Number of subjects: 32
Study 8417772 — intervention group
Group type: COMPARATOR
Intervention: Parental presence (viewing from behind a one-way mirror)
Number of subjects: 32
Study 3804028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus sulpiride 200 mg daily
Number of subjects: 73
Study 3804028 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg daily
Number of subjects: 73
Study 29356277 — intervention group
Group type: COMPARATOR
Intervention: New complex cream composed of Yunnan Portulaca oleracea extract, Prinsepia utilis oil, beta‐glucan, and sodium hyaluronate, applied twice daily for 28 days.
Number of subjects: 20
Study 29356277 — intervention group
Group type: COMPARATOR
Intervention: Control cream (tolerance‐extreme cream), applied twice daily for 28 days.
Number of subjects: 20
Study 29356277 — intervention group
Group type: EXPERIMENTAL
Intervention: New complex cream
Number of subjects: 20
Study 29231520 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick needle insertion therapy at Aqiang point
Number of subjects: 80
Study 29231520 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture at Lianquan (CV 23)
Number of subjects: 80
Study 24758164 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised audit and feedback (A&F) strategies for antibiotic prescribing
Number of subjects: 0
Study 24758164 — intervention group
Group type: COMPARATOR
Intervention: Current audit practice
Number of subjects: 0
Study 21766336 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care Program (SCP)
Number of subjects: 136
Study 21766336 — intervention group
Group type: COMPARATOR
Intervention: Care As Usual (CAU)
Number of subjects: 136
Study 20189926 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity exercise
Number of subjects: 50
Study 20189926 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 50
Study 20189926 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched women without a cancer diagnosis)
Number of subjects: 50
Study 18673366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 315
Study 17058829 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (DFIPRS) in addition to anti-asthmatic medicine
Number of subjects: 71
Study 17058829 — intervention group
Group type: COMPARATOR
Intervention: Anti-asthmatic medicine only (control group)
Number of subjects: 71
Study 14516215 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning about misleading information
Number of subjects: 0
Study 14516215 — intervention group
Group type: COMPARATOR
Intervention: Misleading postevent information
Number of subjects: 0
Study 10834678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine at a renal dose (2.5 microg/kg/min)
Number of subjects: 19
Study 10834678 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 19
Study 10834678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine at higher doses (10 microg/kg/min)
Number of subjects: 19
Study 10834678 — intervention group
Group type: COMPARATOR
Intervention: Neither epinephrine nor dopamine
Number of subjects: 19
Study 10834678 — intervention group
Group type: COMPARATOR
Intervention: Presence of renal failure
Number of subjects: 19
Study 8800254 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterinarians enrolled in a dairy production medicine continuing education program (treatment herds)
Number of subjects: 153
Study 8800254 — intervention group
Group type: COMPARATOR
Intervention: Veterinarians not enrolled in the program (control herds)
Number of subjects: 153
Study 1364078 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (500 mg/day)
Number of subjects: 0
Study 1364078 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (600 mg/day)
Number of subjects: 0
Study 1364078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1364078 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptics
Number of subjects: 0
Study 6370976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (150 mg/day)
Number of subjects: 156
Study 6370976 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 156
Study 6370976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 156
Study 29133604 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142
Study 29133604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study 26820423 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience (MS)
Number of subjects: 293
Study 25022939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patches (maximum maintenance dose of 16 mg/24 h)
Number of subjects: 174
Study 25022939 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 174
Study 25022939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patches
Number of subjects: 174
Study 22465317 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (placebo-controlled trial)
Number of subjects: 2078
Study 22465317 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HDL cholesterol
Number of subjects: 2078
Study 22465317 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 2078
Study 22465317 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 2078
Study 22465317 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest natural quartile of non-HDL cholesterol
Number of subjects: 2078
Study 20009770 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRO 50 mg once daily for 12 weeks
Number of subjects: 111
Study 20009770 — intervention group
Group type: COMPARATOR
Intervention: BFZ 2.5 mg once daily for 12 weeks
Number of subjects: 111
Study 20009770 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRO 50 mg
Number of subjects: 111
Study 20009770 — intervention group
Group type: COMPARATOR
Intervention: BFZ 2.5 mg
Number of subjects: 111
Study 18500597 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycogel dressing
Number of subjects: 100
Study 18500597 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing care
Number of subjects: 100
Study 15926441 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized injection device
Number of subjects: 64
Study 15926441 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 64
Study 12422152 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care BNP assay
Number of subjects: 1050
Study 10351924 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice a day)
Number of subjects: 33
Study 10351924 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 microg twice a day)
Number of subjects: 33
Study 10351924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7496001 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination of 50 mg isoniazid + 120 mg rifampicin + 300 mg pyrazinamide
Number of subjects: 250
Study 7496001 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of the 3 antituberculosis drugs
Number of subjects: 250
Study 7496001 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (triple combination and separate drugs)
Number of subjects: 250
Study 1766329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedagogic format
Number of subjects: 0
Study 1766329 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity format
Number of subjects: 0
Study 1766329 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving format
Number of subjects: 0
Study 7006544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL/kg of 50% dextrose in water (D50W)
Number of subjects: 36
Study 7006544 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water (D5W)
Number of subjects: 36
Study 31726963 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-Aspirin therapy
Number of subjects: 2933
Study 31266924 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile navigation program
Number of subjects: 61
Study 31266924 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61